| 证券代码 | ARMO.O |
| 证券名称 | ARMO BioSciences Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-01-26 |
| 首发价格(元) | 17 USD |
| 首发数量(股) | 7529412 |
| 首发募资额(元) | 128,000,004.00 USD |
| 首发主承销商 | Jefferies LLC,Leerink Partners LLC |
| 货币单位 | USD |
| 公司名称 | ARMO BioSciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 575 Chesapeake Drive, Redwood City, California, USA |
| 成立日期 | 2010-06-23 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.armobio.com |
| 电话 | +1 (650) 779-5075 |
| 传真 | - |
| 公司简介 | ARMO BioSciences, Inc.is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. Its vision is to improve and prolong the lives of cancer patients by advancing and expanding the field of immuno-oncology through novel combinations and treatment sequences of Its pipeline products with standard of care chemotherapies and checkpoint inhibitors or with other emerging immunotherapies that elicit complementary and synergistic treatment effects. |